Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

To fill this gap, large trials such as the Vitamin D and Omega-3 Trial (VITAL) (10) and the Vitamin D Assessment (ViDA) study (11, 12) were started in the early 2010s, with the aim of investigating the effects of high-dose vitamin D3 supplementation on CVD and cancer prevention (Supplemental Table 1).

Source: Introduction. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial: a randomized controlled trial

Source: Article title.

FIND was a 5-year, randomized, double-blind, placebo-controlled supplementation trial of the effects of vitamin D3 on the incidences of CVD and cancer among generally healthy, White, male participants ≥60 years and postmenopausal female participants (≥65 years) from the general Finnish population, conducted in 2012 to 2018.

Source: Methods.

The inclusion criteria were: male participants aged ≥60 years and postmenopausal female participants aged ≥65 years without a history of cancer (except nonmelanoma skin cancer) or CVD (including myocardial infarction, stroke, transient ischemic attack, angina pectoris, coronary artery bypass grafting, or percutaneous coronary intervention).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial: a randomized controlled trial

Randomised controlled trial · The American Journal of Clinical Nutrition · 2022

Original publication title

Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial: a randomized controlled trial

Jyrki K Virtanen; Tarja Nurmi; Antti Aro; Elizabeth R Bertone-Johnson; Elina Hyppönen; Heikki Kröger; Christel Lamberg-Allardt; JoAnn E Manson; Jaakko Mursu; Pekka Mäntyselkä; Sakari Suominen; Matti Uusitupa; Ari Voutilainen; Tomi-Pekka Tuomainen; Sari Hantunen

© The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Vitamin D3 supplementation did not lower the incidences of major CVD events or invasive cancer among older adults, possibly due to sufficient vitamin D status in most participants at baseline.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To investigate the effects of vitamin D3 supplementation on CVD and cancer incidences.

Source: Objectives

Abstract: What methods does the paper describe?

The study was a 5-year, randomized, placebo-controlled trial among 2495 male participants ≥60 years and post-menopausal female participants ≥65 years from a general Finnish population who were free of prior CVD or cancer. The study had 3 arms: placebo, 1600 IU/day, or 3200 IU/day vitamin D3. Follow-up was by annual study questionnaires and national registry data. A representative subcohort of 551 participants had more detailed in-person investigations. The primary endpoints were incident major CVD and invasive cancer. Secondary endpoints included the individual components of the primary CVD endpoint (myocardial infarction, stroke, and CVD mortality), site-specific cancers, and cancer death.

Source: Methods

Abstract: Results

During the follow-up, there were 41 (4.9%), 42 (5.0%), and 36 (4.3%) major CVD events in the placebo, 1600 IU/d (compared with placebo: HR: 0.97; 95% CI: 0.63 to 1.49; P = 0.89), and 3200 IU/d (HR: 0.84; 95% CI: 0.54 to 1.31; P = 0.44) arms, respectively. Invasive cancer was diagnosed in 41 (4.9%), 48 (5.8%), and 40 (4.8%) participants in the placebo, 1600 IU/d (HR: 1.14; 95% CI: 0.75 to 1.72; P = 0.55), and 3200 IU/d (HR: 0.95; 95% CI: 0.61 to 1.47; P = 0.81) arms, respectively.

There were no significant differences in the secondary endpoints or total mortality. In the subcohort, the mean baseline serum 25-hydroxyvitamin D concentration was 75 nmol/L (SD, 18 nmol/L). After 12 months, the concentrations were 73 nmol/L (SD, 18 nmol/L), 100 nmol/L (SD, 21 nmol/L), and 120 nmol/L (SD, 22 nmol/L) in the placebo, 1600 IU/d, and 3200 IU/d arms, respectively.

Source: Results

Abstract: Conclusions

Vitamin D3 supplementation did not lower the incidences of major CVD events or invasive cancer among older adults, possibly due to sufficient vitamin D status in most participants at baseline.

Source: Conclusions
Authors’ abstract

ABSTRACT

Background

Vitamin D insufficiency is associated with risks of cardiovascular diseases (CVD) and cancer in observational studies, but evidence for benefits with vitamin D supplementation is limited.

Objectives

To investigate the effects of vitamin D3 supplementation on CVD and cancer incidences.

Methods

The study was a 5-year, randomized, placebo-controlled trial among 2495 male participants ≥60 years and post-menopausal female participants ≥65 years from a general Finnish population who were free of prior CVD or cancer. The study had 3 arms: placebo, 1600 IU/day, or 3200 IU/day vitamin D3. Follow-up was by annual study questionnaires and national registry data. A representative subcohort of 551 participants had more detailed in-person investigations. The primary endpoints were incident major CVD and invasive cancer. Secondary endpoints included the individual components of the primary CVD endpoint (myocardial infarction, stroke, and CVD mortality), site-specific cancers, and cancer death.

Results

During the follow-up, there were 41 (4.9%), 42 (5.0%), and 36 (4.3%) major CVD events in the placebo, 1600 IU/d (compared with placebo: HR: 0.97; 95% CI: 0.63 to 1.49; P = 0.89), and 3200 IU/d (HR: 0.84; 95% CI: 0.54 to 1.31; P = 0.44) arms, respectively. Invasive cancer was diagnosed in 41 (4.9%), 48 (5.8%), and 40 (4.8%) participants in the placebo, 1600 IU/d (HR: 1.14; 95% CI: 0.75 to 1.72; P = 0.55), and 3200 IU/d (HR: 0.95; 95% CI: 0.61 to 1.47; P = 0.81) arms, respectively.

There were no significant differences in the secondary endpoints or total mortality. In the subcohort, the mean baseline serum 25-hydroxyvitamin D concentration was 75 nmol/L (SD, 18 nmol/L). After 12 months, the concentrations were 73 nmol/L (SD, 18 nmol/L), 100 nmol/L (SD, 21 nmol/L), and 120 nmol/L (SD, 22 nmol/L) in the placebo, 1600 IU/d, and 3200 IU/d arms, respectively.

Conclusions

Vitamin D3 supplementation did not lower the incidences of major CVD events or invasive cancer among older adults, possibly due to sufficient vitamin D status in most participants at baseline.

Publication and source details

Original title: Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial: a randomized controlled trial

Jyrki K Virtanen; Tarja Nurmi; Antti Aro; Elizabeth R Bertone-Johnson; Elina Hyppönen; Heikki Kröger; Christel Lamberg-Allardt; JoAnn E Manson; Jaakko Mursu; Pekka Mäntyselkä; Sakari Suominen; Matti Uusitupa; Ari Voutilainen; Tomi-Pekka Tuomainen; Sari Hantunen

The American Journal of Clinical Nutrition · 2022

Address correspondence to JKV (E-mail: jyrki.virtanen@uef.fi).© The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition.2021https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Academy of Finland10.13039/501100002341 137826

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T02:25:49.613894+00:00

DOI: 10.1093/ajcn/nqab419 · PMC9071497